Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System
Immunology
[키워드] Activation
Administered
Admission
age
ambient
C-reactive protein
C1 esterase inhibitor
Case series
Chest
Clinical improvement
complement
complement system
Computed tomography
Concentration
Conestat alfa
Contact
contact activation system
Controlled clinical trial
COVID-19
declined
dose
dysregulated immune response
Efficacy
elevated
Evidence
hyperinflammation
Immediate
Inflammation
inflammatory cascade
Inflammatory marker
intervals
Intravenous injection
Kallikrein-kinin system
Level
lung involvement
majority
mechanical ventilation
median
Nasopharyngeal swab
occurred
oxygen saturation
oxygen supplementation
Patient
patients
potential benefit
preventing disease
progression
progressive disease
regulator
required
Safe
SARS-CoV-2
severe coronavirus disease
severe COVID-19
severe COVID-19 patients
Severe COVID-19 pneumonia
Switzerland
System
treated
Treatment
University Hospital Basel
[DOI] 10.3389/fimmu.2020.02072 PMC 바로가기 [Article Type] Immunology
[DOI] 10.3389/fimmu.2020.02072 PMC 바로가기 [Article Type] Immunology